Skip to main content
Delfa

← All trials/NCT05196958

DiagMICI

UnknownPhase NA

Interest of GLP1 Analogues in Overweight Type 2 Diabetic Patients With Chronic Inflammatory Bowel Disease

Interest of GLP1 Analogues (aGLP1) in Overweight Type 2 Diabetic Patients With Chronic Inflammatory Bowel Disease (IBD)

Asset

GLP-1 / incretin class catch-all

Listed sites

1

Recruiting sites

1

Estimated enrollment

20

Study population

Obesity / overweight, Type 2 diabetes

Eligibility highlights

•BMI ≥25

Primary endpoints

•Glycemic control•Weight loss

Registered trial locations

Locations reported to ClinicalTrials.gov for this trial snapshot. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT05196958
Org study IDDiagMICI

Timeline

Milestones

Study first posted2022-01-19actual
Study start2022-01-25actual
Last update posted2023-03-07actual
Primary completion2024-01-14estimated
Study completion2024-12-31estimated

Assets

Investigational agents

GLP-1 / incretin class catch-all

Who this study enrolls

Obesity / overweightType 2 diabetes

Who can enroll

Minimum age18 Years
Maximum age75 Years
SexAll
Healthy volunteersNot accepted

Inclusion criteria

•Patients between 18 and 75 years of age
•Patients with inflammatory bowel disease (Crohn's disease (CD) or ulcerative colitis (UC))
•Patient with poorly controlled type 2 diabetes (defined as deviation from the set glycemic target of more than 1% HbA1c)
•Patient with a BMI ≥ 25 kg/m2
•For women of childbearing age: effective contraception* during treatment and up to 5 weeks after discontinuation

* Any contraceptive method used regularly and appropriately that has a low failure rate (i.e., less than 1% per year)

•Patient enrolled in a health insurance plan
•Francophone patient
•Patient with free, informed, written consent

Exclusion criteria

•Patient with a personal or family history of medullary thyroid cancer
•Patient with an active cancer
•Patient with a history of acute or chronic pancreatitis
•Patients with a history of hypersensitivity to GLP1 analogues (or to any other component of the product)
•Patient with a history of severe GI intolerance to GLP-1 receptor agonists
•Patient already included in a risky interventional research protocol (RIPH1)
•Pregnant or breastfeeding women
•Patients with congestive heart failure New York Heart Association (NYHA) class IV
•Patient with end-stage renal disease
•Patients with clinically significant sustained elevation of resting heart rate
•Patient with anti-GAD antibodies in a previous workup at inclusion
•Patient under guardianship or curatorship
•Patient under court protection
•Patient deprived of liberty

Endpoints (7)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Glycemic / diabetes
2
Patient-reported / QoL
2
Other (unclassified)
2
Weight & body composition
1

Weight & body composition

1 endpoint
Primary/protocol endpoint

Weight loss

Time frame:Month 6

descriptive

Glycemic / diabetes

2 endpoints
Primary/protocol endpoint

Glycemic control

Time frame:Month 6

descriptive

Secondary/protocol endpoint

Impact of aGLP1 on the treatment already in place to regulate blood glucose

Time frame:Month 6

descriptive

Patient-reported / QoL

2 endpoints
Secondary/protocol endpoint

Quality of life after 3 months of treatment

Time frame:Month 3

descriptive

Secondary/protocol endpoint

Quality of life after 6 months of treatment

Time frame:Month 6

descriptive

Other (unclassified)

2 endpoints
Secondary/protocol endpoint/low confidence

Tolerance of GLP1 analogues after 3 months of treatment

Time frame:Month 3

descriptive

Secondary/protocol endpoint/low confidence

Tolerance of GLP1 analogues after 6 months of treatment tolerance of GLP1 analogues after 3 and 6 months of treatment

Time frame:Month 6

descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 6, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 6, 2026 snapshot.